FDA priority review sets Aug. 27 decision on Gilead's BIC/LEN switch pill
The once-daily combination must show it holds virologic suppression as well as complex regimens it aims to replace, after Phase 3 data already backed the filing.
Executive Summary
- Gilead is heading toward an FDA decision on a combination pill meant to simplify treatment for HIV patients already on complicated regimens, not to prove a new mechanism works.
- The clinical case behind the filing has already read out, showing the combination held viral suppression comparably to current therapy with no new safety findings, so the decision now turns on regulatory judgment rather than pending trial data.
- Because bictegravir and lenacapavir are each established antiretrovirals, the regulatory question is whether combining them in one tablet preserves that suppression and tolerability rather than whether the mechanism itself works.
- The integrase-inhibitor class is active with several late-stage rivals in testing, so an approval would add a switch option inside a field that already has validated mechanisms rather than opening new therapeutic ground.
The filing
The FDA accepted Gilead's New Drug Application for BIC/LEN and granted priority review, setting a PDUFA action date of August 27, 2026. The application covers adults with HIV who are virologically suppressed but remain on complicated regimens, such as those combining a boosted protease inhibitor with an additional agent, more than one pill a day, or an injectable paired with oral drugs. The combination pairs bictegravir, an integrase inhibitor, with lenacapavir, a capsid inhibitor Gilead describes as carrying no cross-resistance with other antiretroviral classes. U.S+1U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus LenacapavirApr 29, 2026Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenNCT05502341
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The evidence behind it
The NDA rests on Phase 3 data from ARTISTRY-1 (NCT05502341) and a companion trial, ARTISTRY-2 (NCT06333808), both of which evaluated the switch to BIC/LEN in suppressed adults, including patients coming off Gilead's own Biktarvy. At Week 48, BIC/LEN maintained virologic suppression comparable to current therapy and was generally well tolerated, with no new safety signals identified. ARTISTRY-1 enrolled 689 participants across 15 countries and closed enrollment with the trial listed Active, not recruiting. Detailed ARTISTRY-1 results were published in The Lancet in March 2026 and additional data were presented at CROI 2026, including improvements in fasting lipid parameters and treatment satisfaction among patients switching from complex regimens. U.S+1U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus LenacapavirApr 29, 2026Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenNCT05502341
Registry housekeeping
ARTISTRY-1's primary completion date moved twice, from January 2026 to September 1, 2025, and then to September 29, 2025, both changes logged alongside a routine enrollment update from 671 to 689 participants, a 2.7% increase that sits inside the range the trial's own operational model treats as typical. The trial cycled between Recruiting and Active, not recruiting status four times as enrollment closed out normally, a pattern consistent with a study finishing enrollment on schedule rather than one in distress. NCT05502341Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenNCT05502341
The competitive setting
BIC/LEN would compete inside an integrase-inhibitor field that already has validated agents, including ViiV Healthcare's dolutegravir and cabotegravir programs, with several ViiV cabotegravir trials advancing through Phase 3. Against that backdrop, BIC/LEN's role is a same-class, oral single-tablet alternative for patients seeking to simplify off long-acting injectables or multi-pill regimens, competing on convenience and tolerability rather than on a new mechanism.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.